Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.

Actavis PLC (NYSE: ACT) shares spiked 5.77 percent to close at $154.27 a share Tuesday. The stock traded between $151.26 and $154.70 on volume of 3.13 million shares traded. The company reported net revenues were $2.01 billion for the third quarter of 2013, compared to $1.29 billion a year ago. Shares of Actavis have gained approximately 80.0 percent year-to-date.

Get more information on Actavis and free access to the in-depth equity report at:
www.FiveStarEquities.com/ACT

The Goodyear Tire & Rubber Company (NASDAQ: GT) shares declined 5.85 percent to close at $20.76 a share Tuesday. The stock traded between $19.84 and $21.59 on volume 16.81 million shares traded. The company reported net income available to common shareholders was $166 million for the third quarter of 2013, compared to $110 million a year ago. Shares of Goodyear Tire & Rubber have gained approximately 58.0 percent year-to-date.

Get more information on Goodyear Tire & Rubber free access to the in-depth equity report at:
www.FiveStarEquities.com/GT

Huntsman Corporation (NYSE: HUN) shares gained 6.13 percent to close at $23.04 a share Tuesday. The stock traded between $22.37 and $23.25 on volume 8.60 million shares traded. The company reported revenues were $2.84 billion for the third quarter of 2013, an increase of 4.0 percent when compared to a year ago. Shares of Huntsman have gained approximately 45.0 percent year-to-date.

Get more information on Huntsman and free access to the in-depth equity report at:
www.FiveStarEquities.com/HUN

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares declined 2.24 percent to close at $76.09 a share Tuesday. The stock traded between $72.57 and $76.88 on volume of 3.70 million shares traded. The company reported total revenues were $221.7 million for the third quarter of 2013, compared to $336.0 million a year ago. Shares of Vertex Pharmaceuticals have gained approximately 81.0 percent year-to-date.

Get more information on Vertex Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/VRTX

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com